June 11 (Reuters) - Helix Biopharma Corp HBP.TO :
* ANNOUNCES FISCAL THIRD QUARTER 2019 RESULTS
* Q3 LOSS PER SHARE C$0.02
* COMPANY'S LDOS001 CLINICAL STUDY CONTINUES TO FACE PATIENT ENROLMENT CHALLENGES
* HELIX BIOPHARMA - AS AT APRIL 30, 2019, CO HAD WORKING CAPITAL DEFICIENCY OF $2.2 MILLION, SHAREHOLDERS' DEFICIENCY OF $1.9 MILLION AND DEFICIT OF $169.4 MILLION
* SOME OF CO'S VENDORS HAVE PLACED COMPANY ON HOLD (CASH IN ADVANCE) AND IS IMPACTING COMPANY'S CLINICAL DEVELOPMENT PROGRAM
* RE-ALLOCATED LIMITED RESOURCES TO IMPROVE PATIENT ENROLLMENT IN LDOS001 STUDY
* HELIX BIOPHARMA - CASH RESERVES OF $938,000 AS AT APRIL 30, CONTINUE TO BE INSUFFICIENT TO MEET SOME ANTICIPATED CASH NEEDS THROUGH NEXT 12 MONTHS